All News

"Use code 51702 for the routine insertion of an indwelling bladder catheter, such as a Foley," write Jonathan Rubenstein, MD, and Mark Painter.

Colin Goudelocke, MD, describes an abstract presented at the 2024 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting.

The expanded label for 177Lu-PSMA-617 would include patients with mCRPC in the pre-taxane-based chemotherapy setting.

“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.

The authors also project an 85% increase in the number of deaths from prostate cancer per year, which would bring the total number from 375,000 in 2020 to nearly 700,000 by 2040.

"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.

In the monotherapy cohort of TPST-1120, 53% of patients achieved a best response of stable disease, with 5 of those patients remaining on treatment for more than 5 months.

Among the patients who were on treatment for 12 weeks or less, treatment interruptions due to TEAEs occurred in 12.6% of patients, and discontinuations due to TEAEs occurred in 5.3% patients.

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD.

Rohan Garje, MD, discusses recent research linking TP53, RB1, and PTEN mutations with worse overall survival outcomes in prostate cancer.

Convergent plans to conduct phase 2 clinical trials of 225Ac-J591 in prostate cancer in 2024, with a registrational program set to begin in 2025.

Treatment with stereotactic ablative body radiotherapy resulted in no observed local failures or cancer-related deaths among patients with primary renal cell cancer.

The company plans to announce full market availability of the RenaFlex ureteroscope system at a later date.

“The UroLift 2 ATC is designed to deliver the same proven effectiveness of the UroLift System, with significant enhancements on a unified UroLift 2 platform,” says Brian Wilkins.

Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.

“The MODERN trial represents a step towards precision medicine in bladder cancer treatment," says Matthew D. Galsky, MD.

"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.

The novel agent ABSK061 approached a response rate of 40% in patients with advanced solid tumors harboring FGFR2/3 alterations.

“The take-home message is: Don’t assume bad things if the tumor is growing during chemotherapy," says Andrew M. Davidoff, MD.

"At age 73, you must start taking distributions from the account in the form of required minimum distributions (RMDs), which are typically taxable. This means you must include the RMD in your income and pay income tax on the distributed amount," writes Jeff Witz, CFP.

"Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC," says Sia Daneshmand, MD.

The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.

“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option," says Timothy J. Daskivich, MD.

"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.

The AssureMDx test demonstrated an area under the curve of 0.80 in detecting urinary tract recurrences in MIBC.

“These results are encouraging and suggest that circulating biomarkers may be useful in guiding the use of radium-223 therapy,” says David T. Miyamoto, MD, PhD.

In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.

Overall, participating pathologists felt that there is potential to increase diagnostic efficiency by using Ibex Prostate in a clinical setting.